Clinical application of combined anticoagulation therapy in anti-MDA5 antibody-positive associated interstitial lung disease-a retrospective study.

ABSTRACT:

Objective

To explore the clinical efficacy of combined anticoagulation therapy in patients with anti-Melanoma Differentiation-Associated protein 5 (MDA5) antibody-positive associated interstitial lung disease.

Methods

A retrospective cohort study was conducted, which included 100 patients diagnosed with anti-MDA5 antibody-positive interstitial lung disease at our hospital between January 2022 and December 2024. Based on the treatment approach, the patients were divided into two groups: the combined anticoagulation group (receiving conventional therapy plus sequential low-molecular-weight heparin followed by rivaroxaban) and the control group (receiving conventional therapy only). Comparisons were made between the two groups regarding pulmonary function parameters (FVC%, DLCO

SUBMITTER: Zhang T 

PROVIDER: S-EPMC12702877 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature